Sera Prognostics — Third Quarter 2026 Earnings Summary

Sera Prognostics reported a 54% sequential increase in PreTRM test volume for the third quarter of 2026, reaching nearly five times the volume of the first quarter. The company secured Medicaid coverage for the test in Florida, adding approximately 4 million beneficiaries to its covered population, while Illinois Medicaid established a fee schedule of $525 per test. Total PreTRM test revenue for the quarter was $42,000, reflecting a 163% year-over-year increase despite lower average selling prices. The company ended the quarter with $72.8 million in cash and marketable securities, having incurred a net loss of $8.1 million for the three-month period.